<DOC>
	<DOCNO>NCT00001083</DOCNO>
	<brief_summary>For PRAM-1 : To evaluate zidovudine ( ZDV ) + lamivudine ( 3TC ) vs. stavudine ( d4T ) + ritonavir vs. ZDV + 3TC + ritonavir respect change plasma HIV-1 RNA copy number baseline 48 week [ AS PER AMENDMENT 1/5/98 : 72 week ; AS PER AMENDMENT 7/17/98 : 48 week ] stable HIV-infected child &gt; = 16 week prior continuous antiretroviral therapy . To evaluate safety tolerance ZDV + 3TC vs. d4T + ritonavir vs. ZDV + 3TC + ritonavir base upon laboratory clinical toxicity . AS PER AMENDMENT 10/20/97 : For PRAM-1 , Step 2 : To evaluate d4T + nevirapine + ritonavir respect change plasma HIV-1 RNA copy number baseline 48 week child receive least 12 week therapy PRAM-1 ZDV/3TC arm 10,000 viral copy week 12 , 24 , 36 . To evaluate safety tolerance d4T + nevirapine + ritonavir base upon laboratory clinical toxicity . [ AS PER AMENDMENT 10/23/98 : To evaluate safety tolerance switch d4T + ritonavir vs. ZDV + 3TC + ritonavir d4T + indinavir vs. ZDV + 3TC + indinavir stable , HIV-infected child RNA value &lt; = 10,000 copies/ml . ] For PRAM-1 : Evidence support combination therapy 2 antiviral agent beneficial long-term management HIV . The possibility exist combination therapy may result synergistic additive activity prolong period time . Also hypothesize development resistance individual agent develop viral replication significantly decrease . AS PER AMENDMENT 10/20/97 : For PRAM-1 , Step 2 : Interim analysis 12 week PRAM-1 indicate proportion child reach undetectable RNA level ZDV + 3TC arm significantly less two arm . The protocol , therefore , modify ( Step 2 ) permit child ZDV + 3TC arm RNA copy number &gt; = 10,000 opportunity change novel therapeutic regimen ( d4T + nevirapine + ritonavir ) .</brief_summary>
	<brief_title>Comparison New Anti-HIV Drug Combinations HIV-Infected Children Who Have Taken Anti-HIV Drugs</brief_title>
	<detailed_description>For PRAM-1 : Evidence support combination therapy 2 antiviral agent beneficial long-term management HIV . The possibility exist combination therapy may result synergistic additive activity prolong period time . Also hypothesize development resistance individual agent develop viral replication significantly decrease . AS PER AMENDMENT 10/20/97 : For PRAM-1 , Step 2 : Interim analysis 12 week PRAM-1 indicate proportion child reach undetectable RNA level ZDV + 3TC arm significantly less two arm . The protocol , therefore , modify ( Step 2 ) permit child ZDV + 3TC arm RNA copy number &gt; = 10,000 opportunity change novel therapeutic regimen ( d4T + nevirapine + ritonavir ) . The Master PRAM Phase II , multicenter , randomize , open-label trial standard therapeutic regimen current use versus experimental therapy administer 48 week . It design allow new therapeutic arm study `` rolling screen '' multiple generation PRAM . Each PRAM generation compare 2 novel therapeutic arm link arm allows indirect comparison include therapy . Once accrual PRAM-1 complete new treatment comparison open accrual ( PRAM-2 ) . The link arm use PRAM-2 decide Pediatric Primary Scientific Committee . PRAM-2 continue accrue patient PRAM-1 patient continue therapy . For PRAM-1 : This study compare follow three treatment arm : Arm I : ZDV plus 3TC Arm II : d4T plus ritonavir Arm III : ZDV plus 3TC plus ritonavir . Prior randomization one three arm , patient stratify base CD4 percent : either less 15 % great equal 15 % . The first 8 patient randomize Arms II III participate real-time Phase I pharmacokinetic study ( 16 patient total ) . After first 45 ( 15 per arm ) patient enter follow 24 week , interim analysis do . Patients treat 48 week [ AS PER AMENDMENT 1/5/98 : 72 week ] . AS PER AMENDMENT 10/20/97 : PRAM-1 , Step 2 : Patients initially assign Arm I ( ZDV plus 3TC ) RNA value great 10,000 copy week 12 , 24 , 36 assign switch protocol treatment d4T + ritonavir + nevirapine . Patients may enroll Step 2 later week 38 PRAM-1 . [ AS PER AMENDMENT 1/5/98 : Patients initially assign Arm 1 viral load great 100,000 copy may also switch Step 2 discontinue therapy . Patients originally assign Arms I II viral load great 10,000 may continue current drug discontinue study therapy ; viral load great 100,000 discontinue study drug . ] [ AS PER AMENDMENT 7/17/98 : PRAM-1 extended permit long-term follow-up clinically stable , HIV-infected child total 120 week . Patients still initial treatment assignment three treatment arm eligible extension , child PRAM-1 , Step 2 . Step 2 closed enrollment . Patients 3TC/ZDV reach virologic failure must discontinue study therapy ] . [ AS PER AMENDMENT 10/23/98 : PRAM-1 , Step 3 : This amendment substitute indinavir ( IDV ) capsule ritonavir capsule PRAM-1 . The regimen switch d4T plus ritonavir versus ZDV plus 3TC plus ritonavir d4T plus IDV versus ZDV plus 3TC plus IDV . All patient follow 48 week . Patients eligible change regimens take ritonavir capsule RNA value less equal 10,000 copies/ml ( demonstrated recent viral load test ) least 72 week PRAM-1 , Step I. Twelve patient RNA value less equal 400 copies/ml immediately join study ; 6 receive d4T plus IDV 6 receive ZDV plus 3TC plus IDV . Additional patient may add base toxicity viral load result . A total sample size 53 evaluable patient ( 37 RNA value less equal 400 copies/ml 16 RNA value great 400 10,000 copies/ml ) anticipate . PRAM-1 Step 2 patient eligible Step 3 . PRAM-1 , Step 2 patient currently take liquid ritonavir continue study drug ; take ritonavir capsule switch liquid ritonavir go study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : IVIG opportunistic infection prophylaxis allow . Erythropoietin ( EPO ) , granulocyte colonystimulating factor ( GCSF ) granulocytemacrophage colony stimulate factor ( GMCSF ) allow management hematologic toxicity . Treatment trimethoprim allow discretion principal investigator . Patients must : Laboratory evidence ( least 2 viral test ) HIV1 infection . Clinical immunological stability [ maintain CDC category 1 2 immunologic status past 4 month new CDC category ( diagnosis within past year ) ] . Patients must receive continuous antiretroviral therapy past 16 week ( miss 6 week therapy previous 16 week ) . AS PER AMENDMENT 10/20/97 : For PRAM1 , Step 2 : Viral load &gt; = 10,000 &lt; 100,000 copies/ml week 12 , 24 , 36 child initially assign Arm I ( ZDV + 3TC ) PRAM1 currently study . Prior Medication : Required : Patients must receive continuous antiretroviral therapy past 16 week . Allowed : Patients receive immunomodulator therapy part perinatal clinical trial trial HIV expose infant eligible . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Current grade 3/4 clinical laboratory toxicity and/or current grade 2 high amylase/lipase toxicity . Active opportunistic infection and/or serious bacterial infection . Current diagnosis malignancy . Concurrent Medication : Excluded : Current antiretroviral therapy identical follow regimen : ZDV + 3TC , d4T + ritonavir ZDV + 3TC + ritonavir . Concurrent therapy antiHIV1 therapy , biologic response modifier ( EPO , GCSF GMCSF allow ) , human growth hormone megestrol acetate . Use continuous systemic corticosteroid ( &gt; = 14 day duration ) allow . Medications incompatible ritonavir . Probenecid daily intravenous pentamidine . [ AS PER AMENDMENT 10/23/98 : The follow exclude patient receive indinavir : terfenadine , astemizole , cisapride , rifampin , rifabutin , triazolam , ketoconazole , clarithromycin , carbamazepine , phenobarbital , phenytoin , calcium channel blocker , midazolam , ergot derivative . ] Patients follow prior condition symptom exclude : Documented hypersensitivity therapy include treatment arm . Prior Medication : Excluded : Investigational drug therapy within 2 week prior randomization . NOTE : Coenrollment ACTG 219 , ACTG 220 certain ACTG opportunistic infection protocol allow .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>